Qingtai Cao, HanYu Lei, MengLing Yang, Le Wei, YinMiao Dong, JiaHao Xu, Mi Nasser, MengQi Liu, Ping Zhu, LinYong Xu, MingYi Zhao
Hunan Normal University School of Medicine, Changsha, Hunan, China (mainland)
Med Sci Monit 2021; 27:e930032
Available online: 2021-03-08
In December 2019, pneumonia of unknown cause broke out, and currently more than 150 countries around the world have been affected. Globally, as of 5: 46 pm CET, 6 November 2020, the World Health Organization (WHO) had reported 48 534 508 confirmed cases of COVID-19, including 1 231 017 deaths. The novel coronavirus disease (COVID-19) outbreak, caused by the SARS-CoV-2 virus, is the most important medical challenge in decades. Previous research mainly focused on the exploration of lung changes. However, with development of the disease and deepening research, more and more patients showed cardiovascular diseases, even in those without respiratory symptoms, and some researchers have found that underlying cardiovascular diseases increase the risk of infection. Although the related mechanism is not thoroughly studied, based on existing research, we speculate that the interaction between the virus and its receptor, inflammatory factors, various forms of the stress response, hypoxic environment, and drug administration could all induce the development of cardiac adverse events. Interventions to control these pathogenic factors may effectively reduce the occurrence of cardiovascular complications. This review summarizes the latest research on the relationship between COVID-19 and its associated cardiovascular complications, and we also explore possible mechanisms and treatments.
Keywords: Cardiovascular Diseases, Cell Hypoxia, COVID-19, Stress, Physiological, Systemic Inflammatory Response Syndrome